Developer docs
API playgroundTry for free, no card

Search company profiles

Cutaneous Lymphoma Foundation

Full company profile

uuid002zzrt

Namestring
Cutaneous Lymphoma Foundation
Company typeenum
Private
Founded yearint
1998
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWarren, United States
HQ citystring
Warren
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

No data
No data
Differentiator
Functional benefit
Problem solved
No data
Market position
Customer concentration

Classification, Details

No data
API detail

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cutaneous Lymphoma Foundation

Cutaneous Lymphoma Foundation firmographics

Firmographics
Name
Cutaneous Lymphoma Foundation
Website
https://clfoundation.org
Company type
Private
Founded year
1998
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where Cutaneous Lymphoma Foundation is headquartered

Location

Headquarters

HQ city
Warren
HQ country
United States
HQ region
North America

Markets served

Cutaneous Lymphoma Foundation technology and API

Technology

API detail

API docs
API detail

Core technology

AI maturity

App detail

Cutaneous Lymphoma Foundation competitors and assessment

Company assessment

Market position

Customer concentration

Cutaneous Lymphoma Foundation social profiles

Digital presence

Cutaneous Lymphoma Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cutaneous Lymphoma Foundation leadership team

Management profile

Number of profiles

Cutaneous Lymphoma Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cutaneous Lymphoma Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cutaneous Lymphoma Foundation

When was Cutaneous Lymphoma Foundation founded?

Cutaneous Lymphoma Foundation was founded in 1998. It employs 11 to 50 people.

Where is Cutaneous Lymphoma Foundation based?

Cutaneous Lymphoma Foundation is headquartered in Warren, United States, in the North America region.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCitius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in EuropeCitius Oncology presented quality-of-life data from Study 302 of LYMPHIR at the EORTC-CLTG 2026 meeting in Berlin. Among responders, mean Skindex-29 scores improved by 5.38–13.69 points, and 32% of heavily pretreated patients with significant itch saw a sustained decrease. The company will partner with the Cutaneous Lymphoma Foundation on a November 2026 quality-of-life workshop.YahooCitius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in EuropeCitius Oncology presented quality-of-life data from Study 302 of LYMPHIR in relapsed or refractory cutaneous T-cell lymphoma at the EORTC-CLTG 2026 meeting in Berlin. Responders showed sustained improvements in skin-related quality of life, and 32% of heavily pretreated patients with significant itch achieved a clinically meaningful decrease. The company will partner with the Cutaneous Lymphoma Foundation on a November 2026 quality-of-life workshop.MoomooCitius Oncology's Positive Quality of Life Data for LYMPHIR® (Denileukin Diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in EuropeCitius Oncology presented health-related quality of life data from Study 302 of LYMPHIR at the EORTC-CLTG 2026 Annual Meeting in Berlin. Among responders, mean Skindex-29 scores improved by 5.38 to 13.69 points, and 32% of heavily pretreated patients with significant itch achieved a clinically meaningful decrease. The company will partner with the Cutaneous Lymphoma Foundation on a November 2026 quality-of-life workshop.Stock TitanCitius Oncology reports LYMPHIR quality-of-life resultsCitius Oncology presented quality-of-life results from Study 302 of LYMPHIR in relapsed or refractory cutaneous T-cell lymphoma at the EORTC-CLTG 2026 meeting. Responders showed sustained improvements in skin-related quality of life, and 32% of heavily pretreated patients with significant itch achieved a clinically meaningful decrease. The company will partner with the Cutaneous Lymphoma Foundation on a November 2026 quality-of-life workshop.PR NewswireCitius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in EuropeCitius Oncology presented health-related quality of life data from Study 302 of LYMPHIR at the EORTC-CLTG 2026 Annual Meeting in Berlin. Among responders, mean Skindex-29 scores improved by 5.38 to 13.69 points, and 32% of heavily pretreated patients with significant itch achieved a clinically meaningful decrease. The company will partner with the Cutaneous Lymphoma Foundation on a November 2026 quality-of-life workshop.